P/F ratio – Page 4 – Communicable Diseases Research

Flow controlled ventilation in Acute Respiratory Distress Syndrome associated with COVID-19: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-112022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hours adjusted age Alpha approval ARDS arterial pH assumption Blinding BMI chronic cardiovascular chronic respiratory disease Clinical findings Corporation COVID-19 COVID-19 associated ARDS COVID-19 infection develop disease dissemination distress Effect effect size element eligible End exclusion expected Extracorporeal feasibility Flow Flow Controlled Ventilation ICU include inclusion criteria independent intubation less Local lung-protective ventilation maintain mechanical ventilation membrane moderate number objective outcome Oxygenation oxygenation index P/F ratio PaO2 parallel group parameter participant Patient patients PEEP positive power of 80% Pregnancy pressure primary end point Prone position protocol radiological randomisation randomised randomised controlled trial Randomized recruitment Registered respiratory Respiratory failure respiratory rate Sample size SDS sealed severe ARDS status Study protocol subject syndrome the primary endpoint therapy treat Treatment Ventilated ventilated patient Ventilation ventilator Volume website written consent
[DOI] 10.1186/s13063-020-04708-1 PMC 바로가기 [Article Type] Letter

Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

COVID-19 질병으로 고통받는 중환자의 기계적 환기에 대한 항응고, The ANTI-CO 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-09-072022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Abnormalities Administered allergic Anti-Co trial Anticoagulant anticoagulation anticoagulation treatment approval aPTT assumed attending physicians bivalirudin blinded Blinding Clinical improvement Coagulation comparator control group Controlled trial Corporation COVID-19 COVID-19 disease Critically ill patient D-dimer D-dimers dissemination distress dose dropout drug element eligibility eligible exclusion criteria expected experimental group FiO2 for inclusion groups heparin ICU IMPROVE include Inclusion inclusion criteria intervention group intravenously Invasive mechanical ventilation limit Local mechanical ventilation normally distributed number objective on mechanical ventilation outcome P/F P/F ratio PaO2 paO2/fiO2 parallel group parameter participant Patient patients patients with COVID-19 performed Physicians positive power power of 80% Pregnancy Primary outcome protocol randomised randomised controlled trial randomization Randomized receive recruitment Registered registration number respiratory distress Respiratory failure Sample size sample size calculation screened standard treatment status study drug Study protocol subcutaneously subject Taking the mean the patient thrombosis title treated Treatment treatment group Trial registration website
[DOI] 10.1186/s13063-020-04689-1 PMC 바로가기 [Article Type] Letter

The Role of Therapeutic Anticoagulation in COVID-19

Case Report

Published on 2020-08-272022-10-31
Journal: Case Reports in Critical Care [Category] COVID-19,

Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS

Case Report

Published on 2020-07-272022-10-30
Journal: Medicina [Category] COVID-19, SARS,

[키워드] acute respiratory distress acute respiratory distress syndrome (ARDS) Antiviral approach ARDS BMI C-reactive protein calibrated Case report cells clinical condition Coagulation Combination Combined COVID-19 COVID-19 patient Cytokines decrease dropped Dyspnea effort Endothelium Fever hypoxia IL-6 IL-6 receptor immune-mediated inflammation Immunotherapy IMV Inflammation Inflammatory interfere interleukin-6 Intubated Invasive mechanical ventilation Laboratory limit male management monoclonal antibody Neutrophil-to-lymphocyte ratio NIV NLR non-invasive ventilation outcomes Oxygenation P/F P/F ratio PaO Pathogenesis Patient Pneumonia prone positioning Rapid reducing reported response suggested syndrome TCZ therapy Tocilizumab treated Treatment ventilatory strategy with COVID-19 worsening
[DOI] 10.3390/medicina56080377 PMC 바로가기 [Article Type] Case Report

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

Research Paper

Published on 2020-06-302022-10-28
Journal: Aging (Albany NY) [Category] COVID-19, SARS,

[키워드] addition Admission Analysis APACHE II AST AUC BNP Community coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 severity CRP cutoff value defined help identify Illness severity independent risk factor Inflammatory response lactate dehydrogenase (LDH) LDH Lung injury lymphocyte Lymphocytes median age P/F ratio parameters Patient Pneumonia positively correlated Predictive public health emergency Renmin Hospital retrospective risk factor severe cases severe COVID-19 severity of COVID-19 significantly Society SOFA SOFA scores specificity univariable university World Health Organization Wuhan
[DOI] 10.18632/aging.103372 PMC 바로가기 [Article Type] Research Paper